Qiagen N.V.

QIAGEN N.V. delivers comprehensive solutions globally, converting biological specimens into actionable molecular insights. The company offers a broad range of consumables for initial sample preparation, including kits for stabilizing and purifying nucleic acids from diverse biological sources. These facilitate manual or automated processing for applications like genotyping, gene expression analysis, and detecting viral and bacterial pathogens, utilizing technologies such as silica membranes and magnetic beads. Materials for purifying nucleic acids from secondary samples are also available, alongside instruments and accessories vital for nucleic acid purification. Its diagnostic assay portfolio addresses various medical needs, from TB detection via interferon-gamma release, post-transplant monitoring, and viral load measurement, to prenatal screening and identifying STDs and HPV. The company also provides assays for analyzing genomic variations, including mutations, insertions, deletions, and fusions. Integrated sample-to-insight instrumentation supports one-step molecular analysis for complex syndromes and streamlined PCR testing. Furthermore, QIAGEN supplies PCR consumables like quantitative PCR and reverse transcription kits, used in gene expression, genotyping, and gene regulation studies, along with associated instruments and technologies. Solutions extend to human identification and forensics, featuring STR assays and food contamination testing. Their PCR instrument offerings include advanced digital PCR systems, and they develop custom OEM consumables. The company also provides Next-Generation Sequencing (NGS) products, comprising predefined and customizable gene panels, library preparation kits, and whole genome amplification tools. Complementing these are QIAGEN's general consumables, instruments, bioinformatics software, and bespoke laboratory and genomic services. Catering to a diverse client base across molecular diagnostics, academic research, pharmaceuticals, and applied testing, the company maintains strategic partnerships, including agreements with Sysmex Corporation, OncXerna Therapeutics, and Mirati. Established in 1986, its headquarters are located in Venlo, the Netherlands.